Thursday, November 30, 2006

Pfizer's pipeline

forbes gives the highlights of Pfizer's pipeline, which includes 3 drugs targeting kinases:

Axitinib - Sutent successor, firstly for RCC, with picomolar potency vs.VEGFR 1, 2 & 3 and nanomolar potency against PDGFR-beta and KIT, which, according to Forbes is "moving soon into final stage trials for thyroid breast and lung cancer."

CP-751871 - IGFR-1 Ab for prostate and lung cancer, now in P2.

CP-690550: JAK3 inhibitor for RA

I'll dig into Pfizer's news to see what else they're touting.....

2 comments:

Anonymous said...

JAK-3 is hot... it won't be long (if they haven't already) before other companies launch programs to captilize on Pzier's IP position & cmpd template.

Laywers sharpen your pens and protect every IP position there is!

Ann said...

Nice post! You have said it very well. Keep going.